Recruiting

Observational Study

Sponsor:

Ohio State University Comprehensive Cancer Center

Code:

NCT02677961

Conditions

Neoplasms, Connective and Soft Tissue

Bone Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Observation

Study Details

Brief summary:

Translational studies in cancer research can be impeded by the lack of high-quality clinical data that can be correlated with research questions. This is particularly true in the case of rare diseases, such as bone and soft tissue tumors. It is therefore the purpose of this study to create a prospective EHR-based clinical registry for individuals with bone and soft-tissue tumors.

Conditions

Neoplasms, Connective and Soft Tissue

Bone Neoplasms

Study ID

NCT02677961

Start date

Jul 1, 2015

Status verified date

Feb, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Must have a diagnosis or presumed diagnosis of bone or soft tissue tumor as defined by the WHO classification of tumors of soft tissue and bone (4th ed.)
  • Patient, or his/her designated power of attorney, must be able to understand and approve of the consent to participate.

Exclusion Criteria:

  • Prisoners are excluded from participation in the Registry.

Study Design

Enrollment

1500 participants

Anticipated

Interventions and Outcome Measures

Interventions

Observation

Primary outcome measure

  • Overall Survival [ Time Frame: 5 Years ]

Central Contacts and Locations

Central contacts

Locations

Ohio State University

Recruiting

Columbus, Ohio, United States, 43210

Contacts

More Information

Sponsor

Ohio State University Comprehensive Cancer Center

Last update posted

Feb 11, 2026

Last verified

Feb, 2026

Keywords

  • sarcoma
  • registry

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center on 2026-02-11.